Free Trial
NYSEARCA:IHE

iShares U.S. Pharmaceuticals ETF (IHE) Price, Holdings, & News

$69.44 -0.76 (-1.08%)
Closing price 01/31/2025 04:10 PM Eastern
Extended Trading
$69.44 0.00 (0.00%)
As of 01/31/2025 05:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE)

Key Stats

Today's Range
$69.43
$70.23
50-Day Range
$65.15
$70.20
52-Week Range
$62.67
$72.94
Volume
53,415 shs
Average Volume
71,416 shs
Market Capitalization
$701.34 million
Assets Under Management
$600.23 million
Dividend Yield
5.37%
Net Expense Ratio
0.40%
Aggregate Rating
N/A

ETF Overview

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund's investment advisor is BlackRock Fund Advisors.

iShares U.S. Pharmaceuticals ETF Expenses

TypeIHEHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFs
Management Fee0.40%0.57%0.55%0.51%0.52%
Other Expenses0.00%0.30%0.50%0.57%0.54%
Total Expense0.40%0.70%0.72%0.73%0.71%
Fee Waiver0.00%-0.45%-0.51%-0.66%-0.56%
Net Expense0.40%0.61%0.62%0.58%0.60%
Receive IHE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iShares U.S. Pharmaceuticals ETF and its competitors with MarketBeat's FREE daily newsletter.

IHE ETF News Headlines

IHE Contraction Is Not Justified By Fundamental Data
Is this Elon’s true agenda?
All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors have all turned to my business partner and I for our thoughts on the market. And with every investor in America wondering what Elon is going to do now that he's in Washington, this is what we tell them
Healthcare ETFs tumble as UnitedHealth stock weighs
See More Headlines

IHE ETF - Frequently Asked Questions

iShares U.S. Pharmaceuticals ETF's stock was trading at $65.72 at the beginning of 2025. Since then, IHE shares have increased by 5.7% and is now trading at $69.44.
View the best growth stocks for 2025 here
.

iShares U.S. Pharmaceuticals ETF shares split before market open on Thursday, March 7th 2024. The 3-1 split was announced on Thursday, March 7th 2024. The newly issued shares were issued to shareholders after the closing bell on Thursday, March 7th 2024. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

iShares U.S. Pharmaceuticals ETF's top institutional investors include Pallas Capital Advisors LLC (0.58%), Strategic Financial Concepts LLC (0.20%), Strategic Financial Concepts LLC (0.20%) and Grimes & Company Inc. (0.15%).

Shares of IHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that iShares U.S. Pharmaceuticals ETF investors own include Meta Platforms (META), NVIDIA (NVDA), Broadcom (AVGO), Visa (V), Adobe (ADBE), Lam Research (LRCX) and Advanced Micro Devices (AMD).

Fund Details

Issuer
iShares
Fund Name
iShares U.S. Pharmaceuticals ETF
Tax Classification
Regulated Investment Company
Current Symbol
NYSEARCA:IHE
Inception Date
5/1/2006
Fund Manager
Diane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason
Phone
N/A

Fund Focus

Asset Class
Equity
Benchmark
Dow Jones U.S. Select Pharmaceuticals Index
Category
Sector
Focus
Health Care
Development Level
Developed Markets
Region
North America
Number of Holdings
46

Fund Statistics

Assets Under Management
$600.23 million
Average Daily Volume
$73,919.50
Discount/Premium
0.04%

Administrator, Advisor and Custodian

Administrator
Citibank, N.A.
Advisor
BlackRock Fund Advisors
Custodian
Citibank, N.A.
Distributor
BlackRock Investments, LLC
Transfer Agent
Citibank, N.A.
Trustee
N/A
Lead Market Maker
Latour Trading

Options

Optionable
Optionable
Options Volume
1
Put Options
10
Call Options
1
Short Interest
175,200 shs

Miscellaneous

Beta
0.58
Creation Unit
50,000
Creation Fee
$306.00
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report

Top 10 IHE Holdings

IHE Sector Exposure

IHE Industry Exposure


This page (NYSEARCA:IHE) was last updated on 2/1/2025 by MarketBeat.com Staff
From Our Partners